Literature DB >> 32338534

Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy.

Pallavi A Patil1, Xuchen Zhang1.   

Abstract

CONTEXT.—: Immune checkpoint inhibitors (CPIs), including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors, are being increasingly used for treating many advanced malignancies. However, CPI therapy is also associated with gastrointestinal and hepatobiliary adverse effects. OBJECTIVES.—: To review the adverse effects of CPI therapy on the gastrointestinal tract and hepatobiliary system. To describe histopathologic patterns and discuss differential diagnostic considerations in the diagnosis of CPI injuries. DATA SOURCES.—: Published peer-reviewed literature in the English language and personal experience in the diagnosis of CPI injuries. CONCLUSIONS.—: The pathologic manifestations of CPI therapy-induced gastrointestinal and hepatobiliary injury are broad. The patterns of esophageal CPI injury include lymphocytic inflammation and ulcerative esophagitis, while those of gastric injury include chronic active gastritis, lymphocytic gastritis, focal enhancing gastritis, and periglandular inflammation. The duodenal injury may present as duodenitis with villous blunting and granulomas. We also noticed active colitis, microscopic colitis, chronic active colitis, increased apoptosis, ischemic colitis, and nonspecific inflammatory reactive changes in colonic injuries. The reported histologic features of hepatobiliary injuries are panlobular hepatitis, centrilobular necrosis, portal inflammation with bile duct injury, steatosis, nodular regenerative hyperplasia, and secondary sclerosing cholangitis. In summary, we discuss the pathologic features and differential diagnosis of CPI therapy-induced gastrointestinal and hepatobiliary injury. Recognition of CPI injury is important to determine the proper management that often includes cessation of CPI therapy, and administration of steroids or other immunosuppressive agents, based on severity of injury.
© 2021 College of American Pathologists.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32338534     DOI: 10.5858/arpa.2020-0070-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.

Authors:  Qi Ai; Wen Chen; Yonggui Li; Guoqing Li
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 2.  Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Authors:  Naoimh Herlihy; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2022-05-28       Impact factor: 6.866

Review 3.  Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Authors:  Liansha Tang; Jialing Wang; Nan Lin; Yuwen Zhou; Wenbo He; Jiyan Liu; Xuelei Ma
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

4.  Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis.

Authors:  Christopher Ma; Rish K Pai; David F Schaeffer; Jonathan Krell; Leonardo Guizzetti; Stefanie C McFarlane; John K MacDonald; Won-Tak Choi; Roger M Feakins; Richard Kirsch; Gregory Y Lauwers; Reetesh K Pai; Christophe Rosty; Amitabh Srivastava; Joanna C Walsh; Brian G Feagan; Vipul Jairath
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

5.  Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience.

Authors:  Paola Parente; Brigida Anna Maiorano; Davide Ciardiello; Francesco Cocomazzi; Sonia Carparelli; Maria Guerra; Giuseppe Ingravallo; Gerardo Cazzato; Illuminato Carosi; Evaristo Maiello; Fabrizio Bossa
Journal:  Diagnostics (Basel)       Date:  2022-03-11

6.  Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.

Authors:  Sara Hone Lopez; Gursah Kats-Ugurlu; Remco J Renken; Henk J Buikema; Marco R de Groot; Marijn C Visschedijk; Gerard Dijkstra; Mathilde Jalving; Jacco J de Haan
Journal:  Virchows Arch       Date:  2021-08-02       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.